Best Pharma Sector Mutual Funds in India 2026 - Groww Analysis
Stat-callout: The Indian pharma sector is projected to grow at 12% CAGR through FY27, with domestic formulations market reaching ₹4.5 lakh crore (India Brand Equity Foundation).
The pharmaceutical sector remains a cornerstone of India's economy, with homegrown giants like Sun Pharma, Dr. Reddy's, and Cipla leading the charge. As we enter FY27, pharma sector mutual funds offer retail investors exposure to this defensive yet growth-oriented industry. This Groww analysis identifies the top performers for Indian portfolios.
Why Invest in Pharma Funds in India?
India's pharmaceutical industry holds unique advantages:
- Global leadership: Supplies 60% of global vaccines & 20% of generic medicines
- Domestic growth: Rising health awareness post-COVID and increasing insurance penetration
- Regulatory tailwinds: Production Linked Incentive (PLI) scheme boosting API manufacturing
"The Indian pharma sector is transitioning from generics to complex therapeutics, creating multi-year growth opportunities" - Mumbai-based healthcare analyst
Top 5 Pharma Sector Mutual Funds on Groww (2026)
| Fund Name | AUM (₹ cr) | 3Y Returns | Top Holdings |
|---|---|---|---|
| Mirae Asset Healthcare Fund | 8,742 | 18.2% | Sun Pharma, Divi's Labs, Apollo Hospitals |
| ICICI Pru Pharma Healthcare Fund | 5,891 | 16.8% | Dr. Reddy's, Cipla, Biocon |
| SBI Healthcare Opportunities Fund | 4,326 | 15.4% | Lupin, Torrent Pharma, Max Healthcare |
| Nippon India Pharma Fund | 3,715 | 14.9% | Aurobindo Pharma, Glenmark, Laurus Labs |
| UTI Healthcare Fund | 2,983 | 13.7% | Alkem Labs, Ipca Labs, Fortis Healthcare |
Key Trends Shaping Indian Pharma Investments
- Biologics Boom: Indian companies increasing biosimilar capabilities
- China+1 Strategy: Global firms diversifying API sourcing beyond China
- Chronic Disease Focus: Diabetes, cardiovascular drugs seeing 20%+ annual growth
- Diagnostics Expansion: Metropolis, Dr Lal PathLabs expanding tier-2/3 presence
Risks to Consider for Indian Investors
- Price controls: DPCO regulations cap prices of essential drugs
- USFDA scrutiny: Increased inspections at Indian manufacturing sites
- Currency volatility: 60% revenues come from exports (primarily USD)
With the Nifty Pharma index trading at P/E of 28x (vs 22x 5-year average), selective investment through mutual funds remains prudent. The festive season often sees increased healthcare spending, making Diwali an ideal time to review pharma allocations.
For personalised recommendations based on your financial goals, explore our curated fund selections at MarketToMoney.